AQST - Aquestive Therapeutics Inc Stock Price, Fair Value and News

3.11USD-0.17 (-5.18%)Market Closed

Market Summary

USD3.11-0.17

Market Closed

-5.18%

AQST Alerts

Big fall in Revenue (Y/Y)

Big fall in earnings (Y/Y)
Losses in recent quarter

AQST Stock Price

View Fullscreen

AQST RSI Chart

AQST Valuation

Market Cap

283.1M

Price/Earnings (Trailing)

-9.84

Price/Sales (Trailing)

5.68

EV/EBITDA

-10.99

Price/Free Cashflow

-10.64

AQST Price/Sales (Trailing)

AQST Profitability

EBT Margin

-57.26%

Return on Equity

79.24%

Return on Assets

-22.21%

Free Cashflow Yield

-9.4%

AQST Fundamentals

AQST Revenue

Revenue (TTM)

49.8M

Rev. Growth (Yr)

-16.95%

Rev. Growth (Qtr)

4.66%

AQST Earnings

Earnings (TTM)

-28.8M

Earnings Growth (Yr)

-259%

Earnings Growth (Qtr)

-58.16%

Breaking Down AQST Revenue

Last 7 days

0.7%

Last 30 days

-20.7%

Last 90 days

15.6%

Trailing 12 Months

54.7%

How does AQST drawdown profile look like?

AQST Financial Health

Current Ratio

6.28

Debt/Equity

-0.76

Debt/Cashflow

-0.93

AQST Investor Care

Shares Dilution (1Y)

62.79%

Diluted EPS (TTM)

-0.42

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	49.8M	0	0	0
2023	49.9M	49.9M	51.4M	52.3M
2022	52.0M	49.9M	48.1M	47.7M
2021	48.2M	41.9M	46.9M	50.8M
2020	48.7M	59.3M	55.1M	45.8M
2019	56.7M	53.9M	53.0M	52.6M
2018	73.9M	76.7M	62.8M	67.4M
2017	0	0	0	66.9M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Aquestive Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 15, 2024	schobel alexander mark	sold	-300,000	6.00	-50,000	chief innovation/tech officer
Mar 10, 2024	jung cassie	sold (taxes)	-5,524	4.88	-1,132	svp, operations
Mar 10, 2024	wargacki stephen	sold (taxes)	-8,232	4.88	-1,687	svp, research & development
Mar 09, 2024	barber daniel	sold (taxes)	-185,137	4.88	-37,938	president and ceo
Mar 09, 2024	wargacki stephen	sold (taxes)	-54,992	4.88	-11,269	svp, research & development
Mar 09, 2024	boyd peter e.	sold (taxes)	-40,845	4.88	-8,370	see remark
Mar 09, 2024	braender lori j	sold (taxes)	-51,386	4.88	-10,530	svp, general counsel
Mar 09, 2024	jung cassie	sold (taxes)	-40,504	4.88	-8,300	svp, operations
Mar 09, 2024	schobel alexander mark	sold (taxes)	-28,767	4.88	-5,895	chief innovation/tech officer
Mar 09, 2024	toth a ernest jr	sold (taxes)	-57,120	4.88	-11,705	svp, chief financial officer

Which funds bought or sold AQST recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	added	68.59	805,685	1,120,980	-%
May 15, 2024	Altium Capital Management LP	new	-	2,832,900	2,832,900	1.12%
May 15, 2024	Royal Bank of Canada	new	-	128,000	128,000	-%
May 15, 2024	BRIDGEWAY CAPITAL MANAGEMENT, LLC	unchanged	-	431,998	821,567	0.02%
May 15, 2024	TWO SIGMA INVESTMENTS, LP	reduced	-67.25	-104,443	233,218	-%
May 15, 2024	D. E. Shaw & Co., Inc.	new	-	405,607	405,607	-%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	added	278	1,842,760	2,106,340	-%
May 15, 2024	MARSHALL WACE, LLP	sold off	-100	-583,545	-	-%
May 15, 2024	CITADEL ADVISORS LLC	added	33.64	616,413	955,403	-%
May 15, 2024	PRELUDE CAPITAL MANAGEMENT, LLC	new	-	105,631	105,631	0.01%

Are Funds Buying or Selling AQST?

Are funds buying AQST calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own AQST

No. of Funds

Unveiling Aquestive Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 01, 2024	venrock healthcare capital partners iii, l.p.	6.5%	5,555,555	SC 13G
Feb 14, 2024	armistice capital, llc	5.88%	3,924,000	SC 13G
Feb 11, 2022	bratton douglas k	8.6%	3,468,747	SC 13G/A
Feb 16, 2021	perceptive advisors llc	4.1%	1,385,720	SC 13G/A
Feb 09, 2021	bratton douglas k	12.0%	13	SC 13G/A
Dec 01, 2020	madryn asset management, lp	4.2%	1,530,717	SC 13G/A
Feb 14, 2020	perceptive advisors llc	7.0%	2,250,000	SC 13G/A
Feb 12, 2020	bratton douglas k	16.1%	13	SC 13G/A
Sep 09, 2019	madryn asset management, lp	5.5%	1,428,572	SC 13G

Recent SEC filings of Aquestive Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
May 13, 2024	4	Insider Trading
May 13, 2024	4	Insider Trading
May 08, 2024	8-K	Current Report
May 07, 2024	10-Q	Quarterly Report
May 07, 2024	8-K	Current Report
Apr 29, 2024	8-K	Current Report
Apr 26, 2024	3	Insider Trading
Apr 26, 2024	ARS	ARS
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	DEFA14A	DEFA14A

Peers (Alternatives to Aquestive Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	372.2B	85.6B	6.82%	-1.69%	9.67	4.35	5.68%	202.39%
MRK	332.3B	61.4B	4.65%	15.09%	144.1	5.41	6.11%	-82.30%
AMGN	167.7B	29.5B	18.35%	39.38%	44.55	5.68	12.76%	-52.47%
PFE	162.3B	57.8B	12.71%	-21.46%	129.52	2.81	76.51%	-86.81%
GILD	84.4B	27.4B	1.23%	-13.37%	174.21	3.07	1.51%	-91.32%
TEVA	18.4B	16.0B	23.52%	97.09%	-37.29	1.15	7.23%	71.10%
MID-CAP
ALKS	4.1B	1.7B	0.67%	-19.91%	9.41	2.37	54.01%	364.56%
PRGO	4.1B	4.6B	-0.70%	-10.77%	-528.11	0.89	-0.06%	94.55%
BHC	2.5B	9.0B	-21.94%	-21.03%	-5.45	0.28	10.01%	-27.45%
AMPH	2.1B	676.2M	8.56%	-0.82%	13.75	3.14	30.38%	66.04%
SMALL-CAP
TLRY	1.5B	743.2M	15.12%	-18.85%	-4.35	2.06	24.65%	80.36%
TXMD	25.8M	1.3M	18.52%	-47.17%	-3.49	19.84	-98.14%	-104.71%
ACRX	18.4M	89.6M	6.93%	25.60%	-1.29	0.19	287.27%	-129.41%
AGRX	2.5M	21.5M	2.70%	-90.89%	-0.32	0.12	66.16%	61.83%
ACOR	633.5K	115.7M	-50.00%	-97.38%	0	0.01	-2.22%	-352.48%

Aquestive Therapeutics Inc News

Latest updates

Aquestive Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	4.7%	12,053,000	11,516,500	13,002,000	13,241,000	14,513,000	10,682,000	11,463,000	13,265,000	12,270,000	11,078,000	13,287,000	15,345,000	11,122,000	7,149,000	8,260,000	21,675,000	8,765,000	16,419,000	12,418,000	11,129,000	12,643,000
Costs and Expenses	22.7%	21,010,000	17,117,000	15,379,000	17,450,000	15,739,000	21,395,000	20,316,000	26,027,000	22,008,000	-	21,255,000	21,862,000	19,647,000	22,795,000	22,041,000	21,280,000	22,626,000	26,323,000	23,420,000	29,817,000	25,717,000
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	16,373,000	-	-	22,626,000	26,323,000	23,420,000	29,817,000	25,717,000
S&GA Expenses	11.9%	10,689,000	9,550,000	7,385,000	7,360,000	7,455,000	11,812,000	12,459,000	15,587,000	13,021,000	14,981,000	12,129,000	13,134,000	13,231,000	15,582,000	11,803,000	13,894,000	14,613,000	16,474,000	13,714,000	16,246,000	17,908,000
R&D Expenses	105.4%	5,932,000	2,888,000	3,196,000	3,473,000	3,547,000	4,278,000	3,232,000	5,198,000	4,773,000	4,400,000	4,726,000	4,262,000	3,659,000	4,425,000	7,260,000	3,847,000	4,354,000	3,057,000	5,063,000	8,151,000	4,303,000
EBITDA Margin	-36213.4%	-0.39	0.00	-0.10	-0.29	-0.50	-0.95	-1.28	-1.25	-1.10	-1.13	-1.01	-1.19	-	-	-	-	-	-	-	-	-
Interest Expenses	22.5%	2,784,000	2,273,000	1,256,000	1,373,000	1,435,000	1,650,000	1,649,000	1,635,000	1,618,000	1,744,000	2,787,000	2,757,000	2,761,000	2,768,000	2,778,000	2,747,000	2,771,000	2,803,000	2,652,000	1,937,000	1,926,000
Income Taxes	-100.0%	-	101,000	-140,000	284,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	-60.1%	-12,828,000	-8,010,000	-2,175,000	-5,508,000	8,068,000	-12,352,000	-12,536,000	-16,302,000	-13,220,000	-28,945,000	-14,555,000	-12,367,000	-14,672,000	-20,368,000	-16,551,000	-2,334,000	-16,530,000	-12,636,000	-18,412,000	-20,472,000	-14,726,000
EBT Margin	-292.5%	-0.57	-0.15	-0.23	-0.45	-0.66	-1.14	-1.48	-1.46	-1.33	-1.39	-1.32	-1.53	-	-	-	-	-	-	-	-	-
Net Income	-58.2%	-12,828,000	-8,111,000	-2,035,000	-5,792,000	8,068,000	-12,352,000	-12,536,000	-16,302,000	-13,220,000	-28,945,000	-14,555,000	-12,367,000	-14,672,000	-20,368,000	-16,551,000	-2,334,000	-16,530,000	-12,636,000	-18,412,000	-20,472,000	-14,726,000
Net Income Margin	-283.6%	-0.58	-0.15	-0.24	-0.45	-0.66	-1.14	-1.48	-1.46	-1.33	-1.39	-1.32	-1.53	-	-	-	-	-	-	-	-	-
Free Cashflow	-110.0%	-10,413,000	-4,958,000	-2,498,000	-8,733,000	8,814,000	8,390,000	2,592,000	-7,239,000	-14,586,000	-8,594,000	-9,148,000	-1,950,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	125.6%	130	57.00	59.00	57.00	61.00	57.00	52.00	56.00	57.00	62.00	65.00	67.00	62.00	63.00	50.00	64.00	64.00	78.00	49.00	50.00	68.00
Current Assets	176.8%	113	41.00	42.00	40.00	44.00	40.00	38.00	44.00	43.00	47.00	50.00	51.00	44.00	45.00	32.00	44.00	51.00	68.00	38.00	39.00	56.00
Cash Equivalents	298.8%	95.00	24.00	25.00	22.00	27.00	27.00	19.00	18.00	15.00	28.00	31.00	34.00	27.00	32.00	17.00	25.00	36.00	49.00	21.00	22.00	40.00
Inventory	14.3%	8.00	7.00	7.00	6.00	7.00	6.00	7.00	5.00	5.00	4.00	3.00	3.00	3.00	2.00	3.00	3.00	3.00	3.00	4.00	5.00	5.00
Net PPE	-3.2%	4.00	4.00	5.00	5.00	4.00	4.00	4.00	5.00	4.00	5.00	5.00	6.00	6.00	7.00	8.00	8.00	9.00	10.00	10.00	11.00	12.00
Liabilities	1.2%	166	164	162	164	171	176	160	153	150	144	126	121	114	111	87.00	85.00	85.00	85.00	83.00	75.00	74.00
Current Liabilities	-1.4%	18.00	18.00	24.00	39.00	40.00	40.00	37.00	30.00	24.00	22.00	25.00	23.00	20.00	21.00	18.00	15.00	15.00	19.00	20.00	25.00	30.00
Long Term Debt	-100.0%	-	28.00	-	-	-	33.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	65.9%	-36.30	-106	-	-	-109	-118	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-4.0%	-331	-319	-310	-308	-303	-311	-298	-286	-270	-256	-227	-213	-200	-186	-165	-149	-147	-130	-117	-99.43	-78.95
Additional Paid-In Capital	39.1%	296	213	208	202	194	193	191	190	177	175	167	159	149	138	129	128	126	124	83.00	75.00	73.00
Shares Outstanding	32.0%	90.00	69.00	67.00	62.00	56.00	55.00	53.00	45.00	41.00	41.00	39.00	36.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	83.00	-	-	-	28.00	-	-	-	111	-	-	-	102	-	-	-	101	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-110.1%	-10,384	-4,942	-2,347	-7,907	8,816	8,416	2,809	-6,562	-14,482	-8,061	-9,065	-1,756	-14,097	-13,512	-8,313	-9,997	-13,637	-10,575	-14,789	-17,166	-17,680
Share Based Compensation	68.1%	1,580	940	774	631	344	714	535	2,219	913	1,691	1,900	1,721	1,507	1,529	1,427	1,765	1,860	1,872	1,869	1,810	1,520
Cashflow From Investing	-81.2%	-29.00	-16.00	-151	-826	-2.00	-26.00	-1,717	-677	-104	-533	-83.00	-194	-103	-236	-38.00	-112	-131	-86.00	-91.00	-110	-376
Cashflow From Financing	1989.0%	81,741	3,913	4,979	4,287	-9,205	234	-138	10,198	1,298	5,454	6,078	8,686	9,891	28,491	-7.00	10.00	-37.00	39,073	13,629	-493	-2,609

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

AQST Income Statement

2024-03-31

Condensed Statements of Operations and Comprehensive (Loss) Income - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Revenues	$ 12,053,000	$ 11,134,000
Costs and expenses:
Manufacture and supply	4,389,000	4,737,000
Research and development	5,932,000	3,547,000
Selling, general and administrative	10,689,000	7,455,000
Total costs and expenses	21,010,000	15,739,000
Loss from operations	(8,957,000)	(4,605,000)
Other income/ (expenses):
Interest expense	(2,784,000)	(1,435,000)
Interest expense related to royalty obligations	(1,358,000)	0
Interest expense related to the sale of future revenue	(58,000)	(52,000)
Interest income and other income, net	329,000	14,513,000
Loss on extinguishment of debt	0	(353,000)
Net (loss) income before income taxes	(12,828,000)	8,068,000
Income taxes	0	0
Net (loss) income	(12,828,000)	8,068,000
Comprehensive (loss) income	$ (12,828,000)	$ 8,068,000
(Loss) earnings per share attributable to common stockholders:
Basic (in dollars per share)	$ (0.17)	$ 0.15
Diluted (in dollars per share)	$ (0.17)	$ 0.11
Weighted average common shares outstanding:
Basic (in shares)	73,614,710	55,631,947
Diluted (in shares)	73,614,710	73,792,886

AQST Balance Sheet

2024-03-31

Condensed Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 95,200	$ 23,872
Trade and other receivables, net	8,324	8,471
Inventories	7,734	6,769
Prepaid expenses and other current assets	2,121	1,854
Total current assets	113,379	40,966
Property and equipment, net	4,046	4,179
Right-of-use assets, net	5,442	5,557
Intangible assets, net	1,239	1,278
Other non-current assets	5,417	5,438
Total assets	129,523	57,418
Current liabilities:
Accounts payable	10,523	8,926
Accrued expenses	4,637	6,497
Lease liabilities, current	414	390
Deferred revenue, current	1,551	1,551
Liability related to the sale of future revenue, current	910	922
Loans payable, current	23	22
Total current liabilities	18,058	18,308
Notes payable, net	28,759	27,508
Royalty obligations, net	16,119	14,761
Liability related to the sale of future revenue, net	63,626	63,568
Lease liabilities	5,284	5,399
Deferred revenue, net of current portion	31,957	32,345
Other non-current liabilities	2,021	2,016
Total liabilities	165,824	163,905
Contingencies (Note 19)
Stockholders’ deficit:
Common stock, $0.001 par value. Authorized $250,000,000 shares; $90,478,731 and $68,533,085 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	90	69
Additional paid-in capital	295,514	212,521
Accumulated deficit	(331,905)	(319,077)
Total stockholders’ deficit	(36,301)	(106,487)
Total liabilities and stockholders’ deficit	$ 129,523	$ 57,418
Common stock, shares outstanding (in shares)	90,478,731	68,533,085
Common stock, shares issued (in shares)	90,478,731	68,533,085

About Aquestive Therapeutics Inc

Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company's proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. Its proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and AQST-109, an orally delivered epinephrine product candidate for the emergency treatment of allergic reactions, including anaphylaxis. Further, the company develops KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease. Aquestive Therapeutics, Inc. was incorporated in 2004 and is headquartered in Warren, New Jersey.

CEO	Mr. Daniel Barber
WEBSITE	aquestive.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	130

Aquestive Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Aquestive Therapeutics Inc? What does AQST stand for in stocks?

AQST is the stock ticker symbol of Aquestive Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Aquestive Therapeutics Inc (AQST)?

As of Fri May 17 2024, market cap of Aquestive Therapeutics Inc is 283.13 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AQST stock?

You can check AQST's fair value in chart for subscribers.

What is the fair value of AQST stock?

You can check AQST's fair value in chart for subscribers. The fair value of Aquestive Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Aquestive Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AQST so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Aquestive Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether AQST is over valued or under valued. Whether Aquestive Therapeutics Inc is cheap or expensive depends on the assumptions which impact Aquestive Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AQST.

What is Aquestive Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, AQST's PE ratio (Price to Earnings) is -9.84 and Price to Sales (PS) ratio is 5.68. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AQST PE ratio will change depending on the future growth rate expectations of investors.